USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
TERPENOID THERAPEUTICS, INC.
Address:
2501 Crosspark Road
Room B126-MTF
Coralville, IA 52241-
Phone:
(319) 335-3899
URL:
EIN:
120363140
DUNS:
602743903
Number of Employees:
7
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $482,093.00 3
STTR Phase I $232,983.00 2
STTR Phase II $670,417.00 1

Award List:

Novel Glioblastoma Therapeutics

Award Year / Program / Phase:
2007 / STTR / Phase I
Award Amount:
$109,860.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF IOWA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The overall goal of the proposed studies is to establish the feasibility of developing therapies for brain cancers such as glioblastoma multiforme from the schweinfurthin family of antiproliferative agents. These agents are highly toxic to CNS derived tumor cell… More

Improving the Distribution of Geranylgeranyl Diphosphate synthase inhibitors.

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$114,959.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The goal of these studies is the development of a treatment for hormone refractory prostate cancer based on the inhibition of an enzyme geranygeranyl disphosphate synthase (GGDPS). We have developed a group of proprieta ry bisphosphonates containing isoprene… More

Developing Schweinfurthin Analogs as Glioma Therapies

Award Year / Program / Phase:
2009 / STTR / Phase II
Award Amount:
$670,417.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF IOWA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 21,810 cases of primary malignant brain tumor will be reported in the US in 2008. The ACS also estimates that 13,070 deaths will occur due to these diseases in this year. This Phase II STTR program advocates… More

Schweinfurthins: novel treatment for breast cancer

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$204,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): According to the American Cancer Society an estimated 182,000 cases of invasive breast cancer occurred in the US in 2008, with 40,000 deaths due to breast cancer. Among women with metastatic breast cancer, the 5-year su rvival rate is 27%. The studies proposed in… More

Polaris Oncology Survivor Transition (POST) System

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$163,134.00
Agency:
HHS
Principal Investigator:
Jeffrey D. Neighbors – 319-335-1467
Abstract:
DESCRIPTION (provided by applicant): The goal of these studies is to determine the efficacy of proprietary geranylgeranyl diphosphate synthase inhibitors (GGSIs), for inhibition of osteoclast mediated bone resorption in comparison to current standard-of-care agents. We have developed a group of… More